2. Signaling Pathways
  3. Cell Cycle/DNA Damage
  4. Wee1

Wee1

Wee1

Related Products

PDF 0.13 MB

Wee1 is a nuclear kinase belonging to the Ser/Thr family of protein kinases in the fission yeast Schizosaccharomyces pombe (S. pombe). Wee1 has amolecular mass of 96 kDa and it is a key regulator of cell cycle progression. Wee1 influences cell size by inhibiting the entry into mitosis, through inhibiting Cdk1. Wee1 has homologues in many other organisms, including mammals. Wee1 inhibits Cdk1 by phosphorylating it on two different sites, Tyr15 and Thr14. Cdk1 is crucial for the cyclin-dependent passage of the various cell cycle checkpoints. At least three checkpoints exist for which the inhibition of Cdk1 by Wee1 is important: G2/M checkpoint, Cell size checkpoint, DNA damage checkpoint. Wee1 is shown to phosphorylate histone H2B at tyrosine 37 residue which regulates global expression of histones.
WEE1 subfamily includes PMYT1.

Wee1 Isoform Specific Products:

Wee1 Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-176283
    Tubulin/LSD1-IN-1
    		Inhibitor
    Tubulin/LSD1-IN-1 is an effective dual inhibitor of Tubulin polymerization and LSD1 (IC50 = 1.72 μM). Tubulin/LSD1-IN-1 has broad-spectrum antiproliferative activity against cancer cell lines. Tubulin/LSD1-IN-1 inhibits tubulin polymerization by targeting colchicine binding sites, thereby disrupting the microtubule network in gastric cancer cells. Tubulin/LSD1-IN-1 increases the methylation levels of H3K4me1/2 and H3K9me2/3, thereby achieving epigenetic regulation. Tubulin/LSD1-IN-1 induces G2/M arrest, promotes apoptosis, and effectively inhibits colony formation of gastric cancer cells.
    Tubulin/LSD1-IN-1
  • HY-180485
    PROTAC D16-M1P2
    		Degrader
    PROTAC D16-M1P2 is an orally active PKMYT1 PROTAC degrader with a DC50 of 0.7 nM. PROTAC D16-M1P2 also inhibits the activity of PKMYT1 with an IC50 of 7.6 nM. PROTAC D16-M1P2 inhibits pCDK1 with an IC50 of 9 nM. PROTAC D16-M1P2 has demonstrated significant anti-tumor efficacy in mouse models and can be used for research on breast cancer.
    PROTAC D16-M1P2
  • HY-157443
    Myt1-IN-4
    		Inhibitor
    Myt1-IN-4 (21) is an orally active and selective membrane-associated tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1) (Gene name PKMYT1) inhibitor, with an IC50 of 2.6 nM. Myt1-IN-4 (21) possesses antitumor activity.
    Myt1-IN-4
  • HY-168180
    WEE1-IN-11
    		Inhibitor
    WEE1-IN-11 (Compound 13) is a potent CDK2 inhibitor with an IC50 of 2.0 nM. WEE1-IN-11 inhibits NCI–H446, A427, OVCAR3, C33A,and WiDr cells with IC50s of 93.9, 34.5, 86.7, 23.1, and 85 nM, respectively.
    WEE1-IN-11
  • HY-182791
    BAA-009
    		Inhibitor
    BAA-009 is a selective and orally active PKMYT1 inhibitor with an IC50 of <50 nM. BAA-009 inhibits cancer cells proliferation and inhibits tumor growth in OVCAR3 xenograft mice. BAA-009 can be used for the research of cancer, such as ovarian cancer.
    BAA-009
  • HY-143343
    LEB-03-153
    LEB-03-153 is a WEE1 DUBTAC (deubiquitinase-targeting chimera) linking AZD1775 (Adavosertib) to the OTUB1 recruiter EN523 through no linker.
    LEB-03-153
  • HY-160948
    DB07006
    		Inhibitor
    DB07006 (compound 18) is a potent, ATP-cpmpetitive dual inhibitor of Wee1 (IC50 = 0.030 μM) and Chk1 checkpoint kinases (IC50 = 0.018 μM). DB07006 demonstrates effective abrogation of the G2/M checkpoint in combination with DNA-damaging agents in cellular models. DB07006 can be used for cancer research.
    DB07006
  • HY-180893
    XH-30
    		Inhibitor
    XH-30 is a potent, selective, and orally active PKMYT1 inhibitor, with an IC50 of 4.1 nM. XH-30 suppresses the proliferation of P53-mutated triple-negative breast cancer (TNBC) cells by inducing G2/M phase release, DNA damage, and apoptosis. XH-30 demonstrates antitumor effects in an MDA-MB-231 mouse model. XH-30 can be used for P53-mutated TNBC research.
    XH-30
  • HY-108343R
    WEE1-IN-4 (Standard)
    		Inhibitor
    WEE1-IN-4 (Standard) is the analytical standard of WEE1-IN-4 (HY-108343). This product is intended for research and analytical applications. WEE1-IN-4 (Compound 15) is a potent checkpoint Wee1 Kinase inhibitor with an IC50 of 0.011 μM. Wee1 inhibitors can abrogate the G2/M checkpoint.
    WEE1-IN-4 (Standard)
  • HY-162987
    PKMYT1-IN-6
    		Inhibitor
    PKMYT1-IN-6 (compund 98) is a PKMYT1 inhibitor with IC50 less than 50 nM.
    PKMYT1-IN-6
  • HY-162986
    PKMYT1-IN-4
    		Inhibitor
    PKMYT1-IN-4 (compund 27) is a PKMYT1 inhibitor with IC50 less than 50 nM.
    PKMYT1-IN-4
  • HY-N0819R
    Raddeanin A (Standard)
    Raddeanin A (Standard) is the analytical standard of Raddeanin A (HY-N0819). This product is intended for research and analytical applications. Raddeanin A is an oleanane-type triterpenoid saponin with oral activity. Raddeanin A inhibits SRC, mTOR, JNK, VEGFR2, NLRP3 inflammasome, Wnt/β-catenin, Wee1, PI3K/AKT signaling pathway, MAPK/ERK signaling pathway, AR-FL, AR-Vs, and downregulates the expression of p-PI3K and p-AKT. Raddeanin A inhibits osteoclast formation, bone resorption, osteolysis, cancer cell invasion, migration, proliferation, angiogenesis and epithelial-mesenchymal transition, while induces apoptosis, cell cycle arrest, ROS production, immunogenic cell death and dendritic cell maturation. Raddeanin A improves blood-retinal barrier function, alleviates inflammation, regulates the tumor microenvironment, and enhances the activity of anti-PD-1 antibody. Raddeanin A is applicable to the research of breast cancer-associated osteolysis, human osteosarcoma, colorectal cancer, glioblastoma, Alzheimer's disease, cholangiocarcinoma, melanoma, non-small cell lung cancer, castration-resistant prostate cancer and multiple myeloma.
    Raddeanin A (Standard)
  • HY-159937
    PKMYT1-IN-7
    		Inhibitor
    PKMYT1-IN-7 (compound 7) is an orally active PKMYT1 inhibitor with IC50 values of 1.6 nM and 0.06 μM against of PKMYT1 and pCDK1, respectively. PKMYT1-IN-7 suppresses the phosphorylation of CDK1 at T14 and Y15. PKMYT1-IN-7 shows anticancer activity both < and <.
    PKMYT1-IN-7
  • HY-176853
    Myt1-IN-6
    		Inhibitor
    Myt1-IN-6 (Compound formula (1)) is a highly selective MYT1 kinase inhibitor. Myt1-IN-6 is promising for research of RB1-deficient cancers (e.g., triple-negative breast cancer).
    Myt1-IN-6
  • HY-162988
    Myt1-IN-5
    		Inhibitor
    Myt1-IN-5 (compound 4) is a membrane-associated tyrosine and threonine-specific cdc2-inhibitory kinase (Myt1) (Gene name PKMYT1) inhibitor with an IC50 of less than 200 nM.
    Myt1-IN-5
Wee1 Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.